Calithera | Tumor Metabolism and Tumor Immunology | Home

Development Pipeline

Calithera is committed to discovering and developing first-in-class small molecule drugs to fight tumor metabolism and tumor immunology targets differently – and to make a difference for patients.

Development Pipeline

Calithera is committed to discovering and developing first-in-class small molecule drugs to fight tumor metabolism and tumor immunology targets differently – and to make a difference for patients.

Culture

Science

Recent News

November 7, 2018: Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights
October 31, 2018: Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
October 5, 2018: Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day
October 5, 2018: Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839
September 26, 2018: Calithera Biosciences to Host R&D Day and Webcast on October 5, 2018

View All